Journal
NEUROTHERAPEUTICS
Volume -, Issue -, Pages -Publisher
SPRINGER
DOI: 10.1007/s13311-022-01338-0
Keywords
Parkinson's disease; Alpha-synuclein; Progressive; Neuroprotection; Therapy
Ask authors/readers for more resources
The development of neuroprotective therapeutics for Parkinson's disease (PD) is hindered by the lack of translation from pre-clinical to clinical trials. One strategy for improvement is to use extensively characterized animal models, such as Thy1-aSyn line 61 mice, to increase the predictive validity of pre-clinical studies. This model replicates key features of PD and has been extensively studied, leading to a better understanding of the disease and providing a platform for pre-clinical drug testing.
Development of neuroprotective therapeutics for Parkinson's disease (PD) is facing a lack of translation from pre-clinical to clinical trials. One strategy for improvement is to increase predictive validity of pre-clinical studies by using extensively characterized animal models with a comprehensive set of validated pharmacodynamic readouts. Mice over-expressing full-length, human, wild-type alpha-synuclein under the Thy-1 promoter (Thy1-aSyn line 61) reproduce key features of sporadic PD, such as progressive loss of striatal dopamine, alpha-synuclein pathology, deficits in motor and non-motor functions, and elevation of inflammatory markers. Extensive work with this model by multiple laboratories over the past decade further increased confidence in its robustness and validity, especially for analyzing pathomechanisms of alpha-synuclein pathology and down-stream pathways, and for pre-clinical drug testing. Interestingly, while postnatal transgene expression is widespread in central and peripheral neurons, the extent and progression of down-stream pathology differs between brain regions, thereby replicating the characteristic selective vulnerability of neurodegenerative diseases. In-depth characterization of these readouts in conjunction with behavioral deficits has led to more informative endpoints for pre-clinical trials. Each drug tested in Thy1-aSyn line 61 enhances knowledge on how molecular targets, pathology, and functional behavioral readouts are interconnected, thereby further optimizing the platform towards predictive validity for clinical trials. Here, we present the current state of the art using Thy1-aSyn line 61 for drug target discovery, validation, and pre-clinical testing.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available